Your browser is no longer supported. Please, upgrade your browser.
NVS Novartis AG daily Stock Chart
Novartis AG
Index- P/E24.93 EPS (ttm)3.28 Insider Own9.30% Shs Outstand2.65B Perf Week0.98%
Market Cap216.89B Forward P/E14.22 EPS next Y5.75 Insider Trans0.00% Shs Float2.57B Perf Month0.58%
Income7.76B PEG3.85 EPS next Q1.29 Inst Own11.00% Short Float0.06% Perf Quarter-5.96%
Sales50.14B P/S4.33 EPS this Y17.10% Inst Trans0.10% Short Ratio0.81 Perf Half Y-5.41%
Book/sh31.90 P/B2.56 EPS next Y7.42% ROA5.80% Target Price98.06 Perf Year12.03%
Cash/sh- P/C- EPS next 5Y6.48% ROE10.80% 52W Range72.67 - 94.19 Perf YTD-2.69%
Dividend2.98 P/FCF42.73 EPS past 5Y-3.20% ROI7.20% 52W High-15.90% Beta0.78
Dividend %3.65% Quick Ratio0.90 Sales past 5Y-0.70% Gross Margin66.20% 52W Low9.00% ATR1.08
Employees121597 Current Ratio1.20 Sales Q/Q4.80% Oper. Margin17.20% RSI (14)38.80 Volatility0.82% 1.36%
OptionableYes Debt/Eq0.38 EPS Q/Q116.00% Profit Margin15.40% Rel Volume4.43 Prev Close81.70
ShortableYes LT Debt/Eq0.31 EarningsApr 19 BMO Payout82.70% Avg Volume1.81M Price79.21
Recom2.50 SMA20-1.82% SMA50-3.96% SMA200-5.98% Volume4,216,287 Change-3.05%
Jan-25-18Reiterated Leerink Partners Outperform $93 → $100
Dec-06-17Downgrade BofA/Merrill Neutral → Underperform
Jul-26-17Upgrade Morgan Stanley Underweight → Overweight
Jul-05-17Downgrade Credit Suisse Neutral → Underperform
Mar-09-17Initiated Liberum Buy
Mar-08-17Upgrade Societe Generale Hold → Buy
Mar-07-17Downgrade Exane BNP Paribas Neutral → Underperform
Jan-11-17Downgrade Credit Suisse Outperform → Neutral
Nov-10-16Upgrade Argus Hold → Buy
Oct-10-16Reiterated Chardan Capital Markets Buy $95 → $92
Sep-20-16Initiated Chardan Capital Markets Buy $95
Apr-12-16Downgrade Morgan Stanley Equal-Weight → Underweight
Mar-23-16Downgrade Leerink Partners Outperform → Mkt Perform
Jun-22-15Upgrade Bryan Garnier Neutral → Buy
Nov-16-09Initiated Deutsche Securities Buy
Nov-12-09Initiated Barclays Capital Underweight $48
Sep-30-09Upgrade Citigroup Hold → Buy
Sep-15-09Upgrade Jefferies & Co Hold → Buy
Jul-17-09Upgrade JP Morgan Neutral → Overweight
Mar-17-09Initiated Credit Suisse Neutral
Apr-19-18 11:08AM  Novartis Stock Dips After Cosentyx Sales, Sandoz Generics Disappoint Investor's Business Daily
10:05AM  Novartis (NVS) Beats Earnings and Revenue Estimates in Q1 Zacks
09:16AM  SHAREHOLDER ALERT: Monteverde & Associates PC Announces An Investigation Of AveXis, Inc. - AVXS PR Newswire
09:08AM  Sanofi to Divest European Generic Unit, Streamline Business Zacks
08:09AM  Novartis CEO feels heat on U.S. generics, Cosentyx drop Reuters
05:26AM  Novartis: 1Q Earnings Snapshot Associated Press
03:47AM  [$$] Cancer and heart drugs boost Novartis sales Financial Times
03:32AM  Novartis 1Q profit jumps 12 percent as heart drug sales soar Associated Press
02:31AM  [$$] Novartis Buoyed by Heart Drug The Wall Street Journal
02:25AM  [$$] Greek parliament ends probe into bribery allegations Financial Times
Apr-18-18 06:54PM  Roche Hemophilia Drug Gets Breakthrough Therapy Designation Zacks
09:52AM  Amgen's Aimovig Reduces Episodic Migraine in 30% Patients Zacks
Apr-17-18 07:01PM  Glaxo, Novartis Join $4 Billion Gates-Led Push to Fight Malaria Bloomberg
09:55AM  What's in Store for Novartis (NVS) This Earnings Season? Zacks
01:01AM  Novartis tender offer for AveXis commences GlobeNewswire
Apr-16-18 05:14PM  Did Novartis Overpay for AveXis? Motley Fool
05:12PM  How Did Biogen Miss AveXis? Motley Fool
05:08PM  What Novartis Bought in AveXis Motley Fool
08:17AM  The Zacks Analyst Blog Highlights: Agios Pharmaceuticals, BioMarin Pharmaceutical, Vertex Pharmaceuticals and Incyte Zacks
Apr-14-18 07:17AM  3 Biotech Stocks That Soared This Week: Are They Buys? Motley Fool
Apr-13-18 03:20PM  Pharma Stock Roundup: NVS to Buy AveXis, PFE & ABBV's Drugs Succeed in Phase III Zacks
11:51AM  Rigel Pharmaceuticals' (RIGL) Stock Gains 16%: Here's Why Zacks
10:06AM  Gene Therapy in Limelight on Novartis Deal: 3 Stocks in Focus Zacks
09:33AM  Pharma M&A Active This Week: 4 Potential Buyout Targets Zacks
08:18AM  These 3 Biotech Stocks Are Up More Than 500% Over the Last 3 Years Motley Fool
06:41AM  Glaxo to Sell Rare Disease Gene Therapies to Private Biotech Zacks
Apr-12-18 06:00PM  Why One Drug Flop Tanked Incyte's Stock Motley Fool
Apr-11-18 03:00PM  3 Hot Reads From TheStreet's Top Premium Columnists
11:56AM  Alexion's Deal Discipline Sure Beats a Previous Disaster Bloomberg
11:40AM  This Little-Known Company Should Have Gilead's and Celgene's Investors Nervous Motley Fool
10:20AM  Biotech Stock Roundup: Spectrum Up, Incyte Down, AveXis to Merge with Novartis Zacks
Apr-10-18 04:23PM  How These Gene Therapy Stocks Benefit From Novartis-AveXis Deal Investor's Business Daily
03:00PM  Novartis' Acquisition of AveXis Takes Aim at Biogen Motley Fool
10:01AM  Company News For Apr 10, 2018 Zacks
08:10AM  Todays Research Reports on Stocks to Watch: AveXis and Novartis ACCESSWIRE
07:34AM  Novartis and Other Drug Stocks With FDA Catalysts in April Zacks
06:48AM  Focus: Lonza's virus factory shows gene therapy's Texas-sized promise Reuters
06:03AM  Novartis' Acquisition of Avexis: Bad News for Biogen? Motley Fool
04:19AM  Novartis AG -- Moody's: $8.7 billion acquisition of AveXis strengthens Novartis's pipeline in gene therapy, but reduces financial flexibility Moody's
01:01AM  [$$] Novartis Bets $8.7 Billion on Gene-Therapy Company The Wall Street Journal
Apr-09-18 11:51PM  Asian stocks mostly rise as investors weigh trade war fears Associated Press
05:06PM  What Happened in the Stock Market Today Motley Fool
04:21PM  AveXis Pops 80% On Novartis Buyout As Celgene Rumored To Eye Others Investor's Business Daily
04:09PM  Stocks Rise on Softer U.S. Approach in China Trade War
02:11PM  Biotech Bears Get Squeezed The Wall Street Journal
01:38PM  AveXis Pops 80% On Novartis Buyout As Celgene Rumored To Eye Others Investor's Business Daily
01:36PM  Analyst: AveXis M&A Could Support Interest In Regenxbio Benzinga
12:43PM  Why AveXis, Inc. Stock Is Soaring Today Motley Fool
12:42PM  [$$] Why the Deal for AveXis Is a Powerful Vote for Replacement Gene Therapy
12:27PM  AveXis Inc Stock Skyrockets on Novartis Deal InvestorPlace
12:21PM  How a Rockville company benefits from Novartis' $8.7B purchase of a Chicago biotech American City Business Journals
12:13PM  Video: Jim Cramer Reacts to Novartis' Acquisition of AveXis
11:36AM  Novartis Inks $8.7 Billion Gene Therapy Deal to Buy AveXis Zacks
10:41AM  Why Did Novartis Spend $9 Billion On Gene Therapy? CEO Says: 'A Journey To Focus On Data And Digital' Forbes
10:35AM  [$$] Novartis's $9 Billion Bet Is Worth the Risk The Wall Street Journal
10:35AM  Hedge Fund Adage Reaps Big Initial Gain on Health-Care Takeover Bloomberg
10:29AM  Rare Diseases Command Mega Prices With Novartis Wager on AveXis Bloomberg
10:12AM  Morning Movers: AveXis Soars on Novartis Takeover, Boeing Bounces, Leucadia Leaps
09:39AM  Stocks Rise: Facebook Lags; Amazon Jumps; Russia Stocks Rattled Investor's Business Daily
08:37AM  Biogen faces increased 'pressure' after AveXis buyout by Novartis MarketWatch
08:18AM  [$$] Novartis Bets $8.7 Billion on Gene-Therapy Company The Wall Street Journal
07:44AM  Deutsche Bank, Novartis, AveXis, Facebook, Patrick Reed - 5 Things You Must Know
07:25AM  Swiss giant Novartis to buy US-based AveXis in $8.7B deal Associated Press
07:23AM  Novartis buying AveXis for nearly $9 billion Fox Business Videos
07:10AM  Novartis bets big on gene therapy with $8.7 billion AveXis deal Reuters
07:10AM  Biotech Buyer Prays a Monster Premium Will Be Enough Bloomberg
06:46AM  Novartis to buy AveXis in $8.7bn gene-therapy deal Reuters Videos
06:46AM  Novartis bets big on gene therapy with $8.7 billion AveXis deal Reuters
06:37AM  Novartis bets big on gene therapy with $8.7 billion AveXis deal Reuters
06:06AM  Novartis Acquires Gene Therapy Company for $8.7B Investopedia
05:17AM  [$$] Novartis buys US gene therapy group AveXis for $8.7bn Financial Times
03:19AM  Novartis Agrees to Buy AveXis in $8.7 Billion Deal
03:11AM  Novartis bets big on gene therapy with $8.7 bln AveXis deal Reuters
02:46AM  Correct: Novartis to acquire AveXis for $8.7 billion in cash MarketWatch
02:36AM  Novartis to Pay $8.7 Billion for AveXis Bloomberg Video
02:36AM  Novartis to Pay $8.7 Billion for AveXis Bloomberg
01:21AM  [$$] Novartis to buy AveXis for $8.7bn Financial Times
12:59AM  Novartis AG to buy AveXis Inc for $8.7 billion Reuters
12:58AM  Novartis AG to buy AveXis Inc for $8.7 billion Reuters
12:55AM  Novartis to Buy AveXis in $8.7 Billion Gene-Therapy Deal Bloomberg
Apr-06-18 07:05PM  Cramer's lightning round: BlackBerry's CEO doesn't get en... CNBC Videos
04:39PM  U.S. Medicare sets outpatient rate for Yescarta reimbursement Reuters
12:55PM  The Week Ahead In Biotech: PDUFA Dates, IPOs And More Benzinga
09:59AM  The Top 5 Johnson & Johnson Shareholders (JNJ) Investopedia
Apr-05-18 03:49PM  U.S. Medicare sets outpatient rate for Yescarta reimbursement Reuters
03:30PM  8 Biotech Stocks With Clinical Trial Outcomes In April Benzinga
10:47AM  Novartis Announces Data on Cardiovascular Drug Entresto Zacks
Apr-04-18 08:00AM  Todays Research Reports on Stocks to Watch: UroGen Pharma and Novartis ACCESSWIRE
Apr-03-18 04:09PM  Pfizer Takes On Gilead, Novartis With New Deal In Cancer Drugs Investor's Business Daily
Apr-02-18 12:31PM  On World Autism Awareness Day, A Look At Biotech Firms With Potential Treatments In The Pipeline Benzinga
Mar-30-18 09:46AM  The Week Ahead In Biotech: PDUFA Dates, Clinical Trials And Conferences Benzinga
Mar-29-18 04:25PM  Novartis Likely Delayed In Launching Copycat Of Amgen Blockbuster Investor's Business Daily
11:02AM  Exclusive: Penn patient shares the story of her CAR-T cell therapy journey American City Business Journals
Mar-28-18 10:18AM  Company News For Mar 28, 2018 Zacks
10:13AM  Health care trumps terrorism, gun violence concerns for Americans Yahoo Finance Video
09:19AM  In Battle To Cut Drug Prices, Outcome-Based Pricing Carries Big Risks For Biopharma Forbes
09:12AM  Glaxo (GSK) Buys Novartis' Stake in Consumer Healthcare JV Zacks
08:01AM  Novartis AG -- Moody's: Novartis's sale of joint venture stake could be credit positive, but uncertainty around use of proceeds and financial policies persist Moody's
12:34AM  [$$] GSK Buys Novartiss Stake in Health-Care Unit for $13 Billion The Wall Street Journal
12:05AM  [$$] Inside story about the past few weeks of dealmaking at GSK Financial Times
Novartis AG researches, develops, manufactures, and markets a range of healthcare products worldwide. The company's Innovative Medicines segment offers patented prescription medicines to enhance health outcomes for patients and health-care providers. This segment also commercializes products in the areas of oncology and rare diseases, ophthalmology, immunology and dermatology, neuroscience, respiratory, cardio-metabolic, and established medicines. The Sandoz segment provides active ingredients and finished dosage forms of pharmaceuticals in the areas of cardiovascular, central nervous system, dermatology, gastrointestinal and hormonal therapies, metabolism, oncology, ophthalmic, pain, and respiratory; active pharmaceutical ingredients and intermediates primarily antibiotics; protein or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. The Alcon segment offers eye care products, such as eye care devices for cataract, retinal, glaucoma, and refractive surgery, as well as intraocular lenses to treat cataracts and refractive errors; viscoelastics, surgical solutions, surgical packs, and other disposable products for cataract and vitreoretinal surgery; and contact lenses, as well as contact lens care products, including multi-purpose and hydrogen-peroxide based solutions, rewetting drops, and daily protein removers. Novartis AG has collaboration agreements with Xencor; Surface Oncology; Intellia Therapeutics; Caribou Biosciences; Bristol-Myers Squibb; IBM Watson Health; Amgen; Allergan plc; Science 37, Inc.; Bill & Melinda Gates Foundation; and PEAR Therapeutics. Novartis AG was founded in 1895 and is headquartered in Basel, Switzerland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Novartis Bioventures Ltd10% OwnerJul 05Buy15.00266,6674,000,0052,544,182Jul 05 06:05 PM
Novartis Bioventures Ltd10% OwnerJun 19Sale22.023,22070,8992,251,457Jun 20 04:41 PM
Novartis Bioventures Ltd10% OwnerJun 16Sale21.2453,2001,130,2072,254,677Jun 20 04:41 PM
Novartis Bioventures Ltd10% OwnerJun 08Sale22.0070015,4002,307,877Jun 12 04:12 PM
Novartis Bioventures Ltd10% OwnerJun 07Sale22.114,840106,9992,308,577Jun 08 04:33 PM
Novartis Bioventures Ltd10% OwnerJun 06Sale22.987,274167,1612,313,417Jun 08 04:33 PM
Novartis Bioventures Ltd10% OwnerJun 05Sale23.114,780110,4882,320,691Jun 06 04:27 PM
Novartis Bioventures Ltd10% OwnerJun 02Sale23.4714,867348,9492,325,471Jun 06 04:27 PM
Novartis Bioventures Ltd10% OwnerJun 01Sale23.8910,722256,1762,340,338Jun 02 04:25 PM
Novartis Bioventures Ltd10% OwnerMay 31Sale23.9435,539850,8962,351,060Jun 02 04:25 PM
Novartis Bioventures Ltd10% OwnerMay 26Sale25.145,300133,2672,386,599May 30 04:29 PM
Novartis Bioventures Ltd10% OwnerMay 25Sale25.00531,3252,391,899May 30 04:29 PM
Novartis Bioventures Ltd10% OwnerMay 24Sale25.0117,451436,3642,391,952May 25 04:57 PM
Novartis Bioventures Ltd10% OwnerMay 18Sale25.509,019229,9642,409,403May 22 06:50 PM
Novartis Bioventures Ltd10% OwnerMay 17Sale25.5122,534574,9012,418,422May 18 04:36 PM
Novartis Bioventures Ltd10% OwnerMay 16Sale26.3320,081528,7252,440,956May 18 04:36 PM